<DOC>
	<DOCNO>NCT01686321</DOCNO>
	<brief_summary>Bendamustine well tolerable active agent treatment Non Hodgkin 's lymphoma . However , particular aggressive B-cell lymphoma , , small study investigate role bendamustine treatment algorithm . The aim current B-R-ENDA trial investigate efficacy toxicity combination treatment bendamustine subcutaneous rituximab old patient elderly patient high comorbidity qualify CHOP like treatment . The result study form basis large , prospective randomize phase III trial .</brief_summary>
	<brief_title>Rituximab Bendamustine Very Elderly Patients Elderly Medically Non Fit Patients With Aggressive B-cell Lymphoma</brief_title>
	<detailed_description>Bendamustine well tolerable active agent treatment Non Hodgkin 's lymphoma . However , particular aggressive B-cell lymphoma , , small study investigate role bendamustine treatment algorithm . The aim current B-R-ENDA trial investigate efficacy toxicity combination treatment bendamustine subcutaneous rituximab old patient elderly patient high comorbidity qualify CHOP like treatment . The result study form basis large , prospective randomize phase III trial .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Aggression</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Bendamustine Hydrochloride</mesh_term>
	<criteria>Histology : Diagnosis aggressive CD20+ , confirm excisional biopsy lymph node sufficiently extensive biopsy extranodal involvement lymph node involvement . It possible treat follow entity study define new WHO classification 2008 : BNHL , Follicular lymphoma grade IIIb , DLBCL , otherwise specify ( NOS ) , common morphologic variant : centroblastic , immunoblastic , anaplastic , rare morphologic variants.DLBCL subtypes/entities : T cell/histiocyte rich large Bcell lymphoma , primary cutaneous DLBCL , leg type , EBVpositive DLBCL elderly , DLBCL associate chronic inflammation , primary mediastinal ( thymic ) large Bcell lymphoma , intravascular large Bcell lymphoma , ALKpositive large Bcell lymphoma , Plasmoblastic lymphoma , Primary effusion lymphoma , Bcell lymphoma , unclassifiable , feature inter¬mediate diffuse large Bcell lymphoma Burkitt lymphoma , Bcell lymphoma , unclassifiable , feature inter¬mediate diffuse large Bcell lymphoma Hodgkin lymphoma Stage : Any stage accord Ann Arbor Classification Risk group : All risk group ( IPI 1 5 ) Life expectancy Life expectancy least 6 week , lymphoma treat Age : Age elder 81 Age 61 80 CIRS &gt; 6 qualify CHOPtherapy Gender : Performance status : Performance status ECOG 0 3 . The performance status patient assess time registration might initiation prephase treatment , experience show , result significant improvement patient´s performance status . A definition performance status provide Appendix 25.6 Ability give inform consent Written inform consent patient Contract participation sign study center sponsor Already initiate lymphoma therapy ( except prephase treatment first application rituximab ) Serious accompany disorder impair organ function ( except due lymphoma involvement ) , particular : Heart : angina pectoris CCS &gt; 2 , cardiac failure NYHA &gt; 3 ; Lungs : patient exclude resultant pulmonary function test show FEV1 &lt; 50 % diffusion capacity &lt; 50 % reference value : Calculated creatinin clearance &lt; 10 ml/min ( CockcroftGault ) ; Liver : total bilirubin &gt; 3 mg/dl ; Uncontrollable diabetes mellitus ( prephase treatment prednisone ! ) Platelets &lt; 100 000/mm3 , leukocytes &lt; 2500/mm3 ( due lymphoma ) Known hypersensitivity medication use HIVpositivity Acute chronic active hepatitis Poor patient compliance Simultaneous participation treatment study Prior chemo radiotherapy , longterm use corticosteroid antineoplastic drug previous disorder Other concomitant tumor disease and/or tumor disease past 5 year ( except basalioma skin carcinoma situ ) CNS involvement lymphoma ( intracerebral , meningeal , intraspinal ) Active serious infection control oral intravenous antibiotic antifungal Any medical condition opinion investigator place subject unacceptably high risk toxicity . Nonconformity eligibility criterion .</criteria>
	<gender>All</gender>
	<minimum_age>60 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2013</verification_date>
	<keyword>elderly patient</keyword>
	<keyword>bendamustine</keyword>
</DOC>